MBX Biosciences

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

CBIZ to be taken private by Grant Thornton in largest US accounting M&A in 25+ years

Saudi Arabia unveils 14-country maritime coalition to protect Red Sea shipping

WSP Global’s second Arcadis approach fails on price and paper currency concerns

Pakistan coal mine explosion kills at least 32 as rescuers search for 10 trapped workers

MBX Biosciences stock surges 160% after Canvuparatide Phase 2 success in hypoparathyroidism

MBX Biosciences (NASDAQ: MBX) jumps 160% after Canvuparatide Phase 2 success in hypoparathyroidism; see trial data, stock reaction, and Phase 3 outlook.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
Zynga
Zynext Ventures USA LLC

September 22, 2025